natgillin/translations-raw huggingface dataset:
Polysakkariderne er kemisk bundet til stivkrampetoksoidet som et bærerprotein, da dette forbedrer responset på vaccinen, overfladeantigen, dvs. proteiner fra overfladen, fra hepatitis B-virussen.
‘surface antigen’ (proteins from the surface) of the hepatitis B virus.
Polysakkariderne er kemisk forbundet (konjugeret) til tetanus toxoid som bæreprotein, fordi dette forbedrer reaktionen på vaccinen.
The polysaccharides are chemically attached (conjugated) to tetanus toxoid as a carrier protein because this improves the response to the vaccine.
Polysorbat 20 (E 432) Vand til injektionsvæsker
Polysorbate 20 (E432) Water for injections
Polysorbat 20 Natriumchlorid
Polysorbate 20 Sodium chloride
Polysorbat 20 natriumdihydrogenphosphatmonohydrat (til justering af pH-værdien) dinatriumhydrogenphosphatheptahydrat (til justering af pH-værdien) natriumchlorid
Sodium dihydrogen phosphate, monohydrate (for pH adjustment) Disodium hydrogen phosphate, heptahydrate (for pH adjustment) Sodium chloride
Polysorbat 20 Trometamol
Polysorbate 20 Trometamol
Polysorbat 80
Lysine hydrochloride Polysorbate 80
Polysorbat 80
Sucrose Polysorbate 80
Polysorbat 80 (E-433)
Polysorbate 80 (E 433)
Polysorbat 80 (E433) og phosal 50 PG (fosfatidylcholin, propylenglycol, mono- og diglycerider, ethanol, sojafedtsyrer og ascorbylpalmitat).
Polysorbate 80 (E433) and phosal 50 PG (phosphatidylcholine, propylene glycol, mono-and diglycerides, ethanol, soya fatty acids, and ascorbyl palmitate).
Polysorbat 80 (E433) Polyvidon Diethylenglycolmonoethylether Octylacetat
Diethylene glycol monoethyl ether Octyl acetate
Polysorbat 80 (Tween 80) 17 l
Polysorbate 80 (Tween 80) 17 l
Polysorbat 80 1,175 milligram
Polysorbate 80 1.175 milligrams
polysorbat 80 1,175 milligram sorbitantrioleat 1,175 milligram
polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams
polysorbat 80 1,175 milligram sorbitantrioleat 1,175 milligram
qualene 9.75 milligrams polysorbate 80 1.175 milligrams sorbitan trioleate 1.175 milligrams
Polysorbat 80 Ethanol, vandfri
Polysorbate 80 Ethanol anhydrous
Polysorbat 80 Ethanol, vandfri Citronsyre
Polysorbate 80 Ethanol anhydrous Citric acid
Polysorbat 80 Gul jernoxid Rød jernoxid
Polysorbate 80 Iron oxide yellow Iron oxide red
Polysorbat 80 Gul jernoxid Sort jernoxid
Polysorbate 80 Iron oxide yellow Iron oxide black
Polysorbat 80 Gult jernoxid.
Polysorbate 80 Iron oxide yellow
Polysorbat 80 Natriumchlorid
Polysorbate 80 Sodium chloride
Polysorbat 80 og ethanol, vandfri
Polysorbate 80 and ethanol, anhydrous See leaflet for further information.
Polysorbat 80 Povidon
Polysorbate 80 Povidone
Polysorbat 80 Saccharose
Polysorbate 80 Sucrose
Polysorbat 80 Sorbitanoleat
Polysorbate 80 Sorbitan oleate
polysorbat 80 sunset yellow FCF (E110)
polysorbate 80 sunset yellow FCF (E110)
Polysorbat 80 Triethylcitrat
Polysorbate 80 Triethyl citrate
polysorbat 80 vand til injektionsvæsker
Polysorbate 80 Water for injections
Polysorbat 80 Vandfri ethanol Citronsyre
Polysorbate 80 Ethanol anhydrous Citric acid
Polysorbat 80 Vandfri ætanol Citronsyre, vandfri
Polysorbate 80 Ethanol anhydrous Citric acid anhydrous
Polysorbat 80f
Polysorbate 80f
Polyuri
Common
Polyuri
Polyuria
Polyuri Nedsat urinmængde
Polyuria Urine flow decreased
polyuri, hæmaturi, nykturi
Polyuria, haematuria, nocturia
polyvalente ioner).
polyvalent ions)
Polyvinylacetatphthalat Propylenglycol (E1520) Carmin (E120)
Polyvinyl acetate phthalate Propylene glycol (E1520) Carmine (E120)
Polyvinylalkohol (delvist hydrolyseret) (E1203) Talkum (E553B)
Polyvinyl alcohol (partially hydrolysed) (E1203) Talc (E553B)
Polyvinylalkohol (delvist hydrolyseret) Talcum (E553b)
Polyvinyl alcohol (partially hydrolysed) Talc (E553b)
Polyvinylalkohol (delvist hydrolyseret), titandioxid (E 171), macrogol 3000, talkum
Polyvinyl alcohol (partially hydrolysed), titanium dioxide (E 171) macrogol 3000,talc
Polyvinylalkohol (E1203), macrogol 3350 (E1521), titandioxid (E171), talcum (E553B), sunset yellow FCF (E110).
Polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E553B), sunset yellow FCF (E110).
Polyvinylalkohol delvis hydrolyseret Macrogol 4000
Polyvinyl alcohol – part. hydrolyzed Macrogol 4000
Polyvinylalkohol delvist hydrolyseret Titandioxid (E 171)
Polyvinyl alcohol-part. hydrolyzed Titanium dioxide (E171) Macrogol 3350
Polyvinylalkohol delvist hydrolyseret Titandioxid (E 171)
Polyvinyl alcohol-part.hydrolyzed Titanium dioxide (E171) Macrogol 3350
Polyvinylalkohol Talcum Titandioxid (E171)
Polyvinyl alcohol Talc
Polyvinylalkohol Titandioxid Macrogol 3350 Talcum
Polyvinyl alcohol Titanium dioxide Macrogol 3350 Talc
Polyvinylalkohol – delvist hydrolyseret Macrogol 3350
Poly(vinyl alcohol) – partially hydrolysed Macrogol 3350
Polyvinylalkohol – delvist hydrolyseret Titandioxid (E171)
Polyvinyl alcohol-partially hydrolyzed Titanium dioxide (E171)
Polyvinylalkohol, Titandioxid (E171), Macrogol, Talcum, Blå indigocarmin aluminium lake (E132)
Poly(vinyl alcohol), Titanium dioxide (E171), Macrogol, Talc, Blue indigo carmine aluminium lake (E132)
Polyvinylalkohol, titandioxid, macrogol 3350, talcum, gul jernoxid.
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide.
Polyvinylalkohol, titandioxid, macrogol 3350, talcum, indigocarmin aluminiumpigment (E132).
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, indigo carmine aluminium lake (E132).
Polyvinylalkohol, titandioxid, macrogol 3350, talcum, jernoxid, sort (E172).
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172).
Polyvinylalkohol, titandioxid, polyethylenglycol, talcum, rød jernoxid.
Polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red
Polyvinylchlorid (PVC) / polychlortrifluorethylen (PCTFE) / aluminium-blister, der indeholder 7 hårde kapsler.
Polyvinylchloride (PVC) / Polychlorotrifluoroethylene (PCTFE) / Aluminium foil blisters containing 7 hard capsules.
Polyvinylchlorid (PVC) blister med aluminiumsfolie på bagsiden i en karton, der indeholder 30, 60, 90 filmovertrukne tabletter og en multipakning med 180 (2 pakninger med 90) filmovertrukne tabletter.
Polyvinyl chloride (PVC) blisters with aluminium foil backing in a carton containing 30, 60, 90 film- coated tablets and multipacks containing 180 (2 packs of 90) film-coated tablets.
Polyvinylchlorid (PVC)/aluminium blister.Kartoner indeholdende 30 eller 90 depottabletter eller
Cartons containing 30 prolonged- release tablets or 90 prolonged-release tablets. or
Polyvinylkloridpose indeholdende 200 ml, 400 ml eller 800 ml i individuel overtrækspose.
Polyvinylchloride bag containing 200 ml, 400 ml or 800 ml in individual over-pouch.
Polérmiddel
Polishing agent
Polérmiddel
Polishing agent:
Polérmiddel: Carnaubavoks
Polishing agent: carnauba wax.
Polérmiddel: carnaubavoks.
Polishing agent: carnauba wax
Pomalidomid blev fjernet ved hæmodialyse.
Pomalidomide was removed by haemodialysis.
Pomalidomid er til stede i human sæd under behandlingen.
Pomalidomide is present in human semen during treatment.
Pomalidomid forventes at være skadeligt for det ufødte barn og kan give svære og livstruende fødselsdefekter.
Pomalidomide is expected to be harmful to the unborn child, causing severe and life-threatening birth defects.
Pomalidomid krydsede placenta og blev detekteret i fosterets blod efter administration til drægtige kaniner.
Pomalidomide crossed the placenta and was detected in foetal blood following administration to pregnant rabbits.
Pomalidomid skal seponeres permanent for angioødem, grad 4 udslæt, eksfoliativt eller bulløst udslæt.
Pomalidomide must be discontinued permanently for angioedema, Grade 4 rash, exfoliative or bullous rash.
Pomalidomid virker på flere måder i multipelt myelom i lighed med andre immunmodulerende midler, f.eks. lenalidomid og thalidomid: Det blokerer udviklingen af tumorceller, forhindrer vækst af blodkar i tumorer og stimulerer også nogle af de specialiserede celler i immunsystemet til at angribe tumorcellerne.
Pomalidomide works in a number of ways in multiple myeloma, similarly to other immunomodulating agents such as lenalidomide and thalidomide: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and also stimulates some of the specialised cells of the immune system to attack the tumour cells.
Pomelidomide Celgene er blevet undersøgt i en hovedundersøgelse, der involverede 455 voksne med multipelt myelom, hvis sygdom ikke reagerede på eller vendte tilbage efter tidligere behandlinger.
Imnovid has been studied in one main study involving 455 adults with multiple myeloma, whose disease did not respond to or came back after previous treatments.
Pomezia (Rom) Italien
00071 Pomezia (Rome) Italy
Pompes sygdom med debut i spædbørnsalderen
Infantile-onset Pompe disease
Pompes sygdom med debut i spædbørnsalderen; klinisk forsøg med patientalder fra 6 måneder til 3,5 år
Infantile-onset Pompe disease; clinical trial in patients aged 6 months to 3.5 years
Pompes sygdom tilhører de lysosomale aflejringssygdomme, idet den skyldes en mangel på en naturligt forekommende lysosomal hydrolase, sur α-glukosidase (GAA), der nedbryder lysosomal glykogen til glukose.
Pompe disease belongs to the lysosomal storage disorders as it is caused by a deficiency of a naturally-occurring lysosomal hydrolase, acid α- glucosidase (GAA) that degrades lysosomal glycogen to glucose.
Ponatinib fortrænges ikke ved samtidig administration af ibuprofen, nifedipin, propranolol, salicylsyre eller warfarin.
0.96. Ponatinib is not displaced by concomitant administration of ibuprofen, nifedipine, propranolol, salicylic acid, or warfarin.
Ponatinib fremkaldte skrumpning af tumor og længere overlevelse hos mus med tumorer, som havde naturligt forekommende eller T315I-mutant BCR-ABL.
Ponatinib elicited tumour shrinkage and prolonged survival in mice bearing tumours expressing native or T315I mutant BCR-ABL.
Ponatinib udskilles ikke primært via nyrerne.
Renal excretion is not a major route of ponatinib elimination.
Ponatinibs blod/plasma-forhold er 0,96.
The blood/plasma ratio of ponatinib is
pontan abort. azoospermi (manglende sædproduktion).
pontaneous abortion. azoospermia (lack of sperm production).
pontan abort. zoospermi (manglende sædproduktion).
pontaneous abortion. azoospermia (lack of sperm production).
pontan blødning
pontaneous bleeding
pontan erektion
pontaneous erection
pontan rejsning uden seksuel stimulation
pontaneous erection without sexual stimulation
pontane indberetninger,
pontaneous reporting,
Poolede data fra de tre placebokontrollerede, 6-ugers forsøg med fast dosis af orale paliperidon- depottabletter (3, 6, 9 og 12 mg) viser, at der blev rapporteret ortostatisk hypotension hos 2,5 % af forsøgspersonerne, der blev behandlet med oral paliperidon, sammenlignet med 0,8 % af forsøgspersonerne, der blev behandlet med placebo.
Based on pooled data from the three placebo-controlled, 6-week, fixed-dose trials with oral paliperidone prolonged release tablets (3, 6, 9, and 12 mg), orthostatic hypotension was reported by 2.5% of subjects treated with oral paliperidone compared with 0.8% of subjects treated with placebo.
Poolede DUET- studier
Pooled DUET Studies
Poolede studier (046, 047, 074)
Pooled studies (046, 047, 074)
Pooling af følgende klasser af antihypertensiva: Diuretika, beta-blokkere, ACE-hæmmere, angiotensin II antagonister, antihypertensiva (vasodilatatorer og centralt virkende), adrenerge neuroblokkere, calciumblokkere og alfa-adrenerge receptorblokkere viste ingen forskel i bivirkningsprofil hos patienter, som tog sildenafil sammenlignet med placebobehandling.
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally- acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.
Pooling af følgende klasser af antihypertensiva: Diuretika, beta-blokkere, ACE-hæmmere, angiotensin II antagonister, antihypertensiva (vasodilatatorer og centralt virkende), adrenerge neuroblokkere, calciumblokkere og alfa-adrenerge receptorblokkere viste ingen forskel i bivirkningsprofil hos patienter, som tog sildenafil sammenlignet med placebobehandling.
Pooling of the following classes of antihypertensive medication; diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrally- acting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.
Popliteal og brakial perfusion kræver sjældent mere end 1 l.
Popliteal and brachial perfusions may not need more than 1 litre.
Population evaluerbar for respons
Response Evaluable Population
Population med KRAS-vildtype Population med KRAS-mutation
KRAS wild-type population KRAS mutant population
Population med muteret RAS
Mutant RAS population
Population med overekspression af HER2
HER2-Overexpressing Population
Population med RAS-vildtype Population med RAS-mutation
RAS wild-type population RAS mutant population
Population med vildtype-RAS
Wild-type RAS population
Population ved den primære PFS-analyse
Primary PFS analysis Population
PopulationBefolkningsfarmakokinetisk evaluering har ikke vist tegn på at rygning skulle påvirke aripiprazols farmakokinetik i klinisk signifikant
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
populatione n = 668
populatione n=668
Populationen af alle evaluerbare patienter (ITT) (N=41)
All Evaluable Patients (ITT) Population (N=41)
Populationen af non-responders omfattede 2 undergrupper: patienter med tidligere partial response (≥ 2 log10 reduktion i HCV-RNA i uge 12, men uden ikke- detekterbart HCV-RNA ved afsluttet behandlingen med et pegyleret interferon og ribavirin) og patienter med tidligere null response (<2 log10 reduktion i HCV-RNA i uge 12 af den tidligere behandling med pegyleret interferon og ribavirin).
The non-responder-population was comprised of 2 subgroups: prior partial responders (greater than or equal to 2 log10 reduction in HCV RNA at week 12, but not achieving HCV RNA undetectable at end of treatment with a peginterferon and ribavirin) and prior null responders (less than 2 log10 reduction in HCV RNA at week 12 of prior treatment with peginterferon and ribavirin).
Populationen i forsøgene var 26 til 90 år gamle (59 % kvinder, 41 % mænd,
The population in the trials was 26 to 90 years of age (59% female, 41% male;
Populationen omfattede 164 patienter (perampanel N=82, placebo N=82).
The population included 164 patients (perampanel N=82, placebo N=82).
Populationen, som indgår i influenzabehandlingsstudierne, består af i øvrigt raske voksne/unge og patienter ”i risiko” (patienter med en højere risiko for at udvikle komplikationer i forbindelse med influenza, f.eks. ældre patienter og patienter med kronisk hjerte-eller luftvejssygdom).
The population included in the influenza treatment studies is comprised of otherwise healthy adults/adolescents and patients “at risk” (patients at higher risk of developing complications associated with influenza, e.g. older people and patients with chronic cardiac or respiratory disease).
Populationen, som indgår i influenzabehandlingsstudierne, består af i øvrigt raske voksne/unge og patienter ”i risiko” (patienter med en højere risiko for at udvikle komplikationer i forbindelse med influenza, f.eks. ældre personer og patienter med kronisk hjerte-eller luftvejssygdom).
The population included in the influenza treatment studies is comprised of otherwise healthy adults/adolescents and patients “at risk” (patients at higher risk of developing complications associated with influenza, e.g. older people and patients with chronic cardiac or respiratory disease).
Populationens gennemsnitlige totale clearance er beregnet til 0,445 l/t (27,2 % CV).
The population mean total clearance is estimated at 0.445 L/h (27.2 % CV).
populationg n = 667
populationg n=667
populationg n=667
IFM-2005-01
Populations- eliminationshalveringstiden estimeret ved den populationsfarmakokinetiske analyse for vemurafenib er 51,6 timer (det 5. og 95. percentil-interval for de individuelle estimater for halveringstid er 29,8 - 119,5 timer).
The population elimination half-life estimated by the population PK analysis for vemurafenib is 51.6 hours (the 5th and 95th percentile range of the individual half-life estimates is 29.8 - 119.5 hours).
Populations-baseret analyse viser, at alder over det undersøgte område (21 – 75 år) ikke signifikant ændrer farmakokinetikken af Caelyx.
Population based analysis demonstrates that age across the range tested (21–75 years) does not significantly alter the pharmacokinetics of Caelyx.
Populations-farmakokinetisk analyse af Victrelis indikerede, at alder ikke havde nogen effekt på eksponering.
Population pharmacokinetic analysis of Victrelis indicated that age had no apparent effect on exposure.
Populations-farmakokinetisk analyse af Victrelis indikerede, at race ikke havde nogen effekt på eksponering.
Population pharmacokinetic analysis of Victrelis indicated that race had no apparent effect on exposure.
Populations-farmakokinetiske resultater (i det undersøgte område for creatinin clearance 30 -
Population pharmacokinetic data (in the range of creatinine clearance tested of
populationsanalyser tyder på at
PK studies suggest that a dose
Populationsanalyser viste, at for en patient med en kreatininclearance på 20 ml/min (svært nedsat nyrefunktion) eller på 50 ml/min (moderat nedsat funktion), skulle den tilsvarende forventede clearance af zoledronsyre være henholdsvis 37 % eller 72 % af clearance hos en patient med en kreatininclearance på 84 ml/min.
Population analysis showed that for a patient with creatinine clearance of 20 ml/min (severe renal impairment), or 50 ml/min (moderate impairment), the corresponding predicted clearance of zoledronic acid would be 37% or 72%, respectively, of that of a patient showing creatinine clearance of 84 ml/min.
Populationsfarmakokinetikken blev analyseret for at evaluere virkningen af de demografiske karakteristika.
The population pharmacokinetics were analysed to evaluate the effects of demographic characteristics.
Populationsfarmakokinetisk analyse af hiv-inficerede patienter i fase 2- og fase 3-studier af Genvoya viste, at inden for det undersøgte aldersinterval (12 til 82 år) havde alder ikke nogen klinisk relevant virkning på eksponeringer for tenofoviralafenamid.
Population pharmacokinetics analysis of HIV-infected patients in Phase 2 and Phase 3 studies of Genvoya showed that within the age range studied (12 to 82 years), age did not have a clinically relevant effect on exposures of tenofovir alafenamide.
Populationsfarmakokinetisk analyse har ikke påvist effekt af MTX, non-steroide antiinflammatoriske midler (NSAIDs) eller kortikosteroider på tocilizumabs clearance.
Population pharmacokinetic analyses did not detect any effect of MTX, non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids on tocilizumab clearance.
Populationsfarmakokinetisk analyse hos særlige populationer
Population pharmacokinetic analysis in special populations
Populationsfarmakokinetisk modellering indikerer, at eksponeringerne omtrent fordobles hos patienter med svært nedsat nyrefunktion (CrCl 15 – 29 ml/min) i forhold til patienter med normal nyrefunktion.
Population PK modeling indicates that exposure approximately doubles in patients with severe renal impairment (CrCL 15 – 29 mL/min) relative to patients with normal renal function.
Populationsfarmakokinetisk modellering viste, at en dosis på 10 mg/kg til børn under 4 måneder vil være tilstrækkelig til at opnå måleksponeringen til behandling af Candida-infektioner i CNS.
Population PK modeling demonstrated that a dose of 10 mg/kg in children less than 4 month of age would be sufficient to achieve the target exposure for the treatment of CNS Candida infections.
Populationsfarmakokinetisk/farmakodynamisk modellering viste, at reduktionen af total og tonisk- atonisk anfaldsfrekvens, forbedringen af den samlede evaluering af sværhedsgraden af anfald og øgningen af sandsynligheden for reduktion af anfaldsfrekvensen var afhængig af rufinamidkoncentrationerne.
Population pharmacokinetic/pharmacodynamic modelling demonstrated that the reduction of total and tonic-atonic seizure frequencies, the improvement of the global evaluation of seizure severity and the increase in probability of reduction of seizure frequency were dependent on rufinamide concentrations.
Populationsfarmakokinetisk/farmakodynamisk modellering viste, at reduktionen af total og tonisk- atonisk anfaldshyppighed, forbedringen af den samlede evaluering af sværhedsgraden af anfald og den forhøjede sandsynlighed for reduktion af anfaldshyppigheden var afhængig af rufinamidkoncentrationerne.
Population pharmacokinetic/pharmacodynamic modelling demonstrated that the reduction of total and tonic-atonic seizure frequencies, the improvement of the global evaluation of seizure severity and the increase in probability of reduction of seizure frequency were dependent on rufinamide concentrations.
Populationsfarmakokinetiske analyser af demografiske data tyder på, at dosisjustering ikke er nødvendig med hensyn til vægt eller Eastern Cooperative Oncology Group (ECOG) score.
Population pharmacokinetic analyses of demographic data indicate that no starting dose adjustments are necessary for weight or Eastern Cooperative Oncology Group (ECOG) performance status.
Populationsfarmakokinetiske analyser af kliniske undersøgelsesdata af pulmonal arteriel hypertension tyder på en reduktion af sildenafils clearance og/eller en stigning i oral biotilgængelighed, ved administration sammen med CYP3A4-substrater og kombinationen af CYP3A4-substrater og beta- blokkere.
Population pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data indicated a reduction in sildenafil clearance and/or an increase of oral bioavailability when co-administered with CYP3A4 substrates and the combination of CYP3A4 substrates and beta-blockers.
Populationsfarmakokinetiske analyser hos CML-patienter har vist, at alder har en lille effekt på fordelingsvolumen (12 % stigning hos patienter 65 år).
Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12 % increase in patients > 65 years old).
Populationsfarmakokinetiske analyser hos patienter med Ph+ leukæmi eller maligne solide tumorer tyder på, at alder, køn, legemsvægt og race ikke har nogen klinisk relevante effekter.
Population pharmacokinetic analyses in patients with Ph + leukaemia or malignant solid tumour indicate that there are no clinically relevant effects of age, gender, body weight, race.
Populationsfarmakokinetiske analyser indikerer, at kropsvægt (33-135 kg), køn, race og typen af hæmatologisk malignitet (MM, MDS eller MCL) ikke har nogen klinisk relevant virkning på lenalidomids clearance hos voksne patienter.
Population pharmacokinetic analyses indicate that body weight (33- 135 kg), gender, race and type of haematological malignancy (MM, MDS or MCL) do not have a clinically relevant effect on lenalidomide clearance in adult patients.
Populationsfarmakokinetiske analyser indikerer, at reslizumabs farmakokinetik ikke er signifikant forskellig mellem etniske grupper (hvide, sorte og asiater).
Population pharmacokinetic analyses indicated that the pharmacokinetics of reslizumab is not significantly different between ethnic groups (white, black and Asian).
Populationsfarmakokinetiske data for Xolair blev analyseret for at evaluere effekten af demografiske karakteristika.
The population pharmacokinetics of Xolair were analysed to evaluate the effects of demographic characteristics.
Populationsfarmakokinetiske data indikerede, at køn ikke har signifikant indflydelse på ibrutinib- clearance fra kredsløbet.
Population pharmacokinetics data indicated that gender does not significantly influence ibrutinib clearance from the circulation.